Key Takeaway
Low-dose aspirin reduces major cardiovascular events in diabetic patients, with greater absolute benefit in those at higher baseline cardiovascular risk, though bleeding risk persists across risk strata.
Summary
This meta-analysis focused specifically on the role of low-dose aspirin in primary prevention of cardiovascular disease among patients with diabetes mellitus, a population at elevated baseline cardiovascular risk. The study stratified results by baseline cardiovascular risk level to determine where aspirin provides the greatest net benefit.
The pooled analysis found that low-dose aspirin significantly reduced the risk of major adverse cardiovascular events (MACE) in diabetic patients overall. When stratified by baseline risk, the absolute benefit was greater in patients with higher cardiovascular risk scores, supporting a risk-stratified approach to aspirin prescribing in this population.
However, the increased bleeding risk associated with aspirin was present across all risk strata. The authors concluded that in diabetic patients, aspirin for primary prevention should be considered primarily in those with elevated cardiovascular risk where the expected benefit outweighs the bleeding hazard, aligning with current guideline recommendations for individualized decision-making.